About EndoSphere Inc.
EndoSphere Inc. is a pioneer of endoscopically-insertable medical technologies. Founded in 2006, EndoSphere has developed a broad IP portfolio including 29 issued and pending U.S. and international patents. The company’s flagship product, the SatiSphere™ System, is a non-invasive treatment for one of the world’s largest health issues: Metabolic Diseases including Obesity and Type II Diabetes. The SatiSphere device improves the regulation of appetite and satiety by using the body’s natural physiology – providing an incisionless, reversible, and repeatable solution. Clinical studies have shown that the SatiSphere device enables obese patients to achieve significant weight loss without the need for surgery or medication. The device has received CE Mark regulatory approval for commercialization in 31 countries.
2011 Industry Conference featuring EndoSphere's Chief Medical Officer and Founder Kenneth Binmoeller, MD
EndoSphere CEO James McKinley describes the SatiSphere™ technology